Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Takeda Pharma (TKPYY)

Takeda Pharma (TKPYY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 25,919,552
  • Shares Outstanding, K 1,562,360
  • Annual Sales, $ 15,935 M
  • Annual Income, $ 1,682 M
  • 60-Month Beta 0.42
  • Price/Sales 1.64
  • Price/Cash Flow N/A
  • Price/Book 1.36
Trade TKPYY with:
  • Price/Earnings ttm 12.22
  • Earnings Per Share ttm 1.37
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 02/07/19
  • Annual Dividend & Yield 0.58 (3.48%)
  • Most Recent Dividend 0.288 on 09/27/18
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
15.5000 +7.03%
on 12/18/18
19.2300 -13.73%
on 11/26/18
-2.6300 (-13.68%)
since 11/21/18
3-Month
15.5000 +7.03%
on 12/18/18
21.9399 -24.38%
on 09/26/18
-4.3650 (-20.83%)
since 09/21/18
52-Week
15.5000 +7.03%
on 12/18/18
31.2900 -46.98%
on 02/01/18
-11.8100 (-41.58%)
since 12/21/17

Most Recent Stories

More News
Takeda to Divest Four Diabetes Products in Japan to Teijin Pharma Limited

Takeda Pharmaceutical Company Limited (TOKYO:4502) (NYSE:TAK) ("Takeda") today announced that it has entered into an agreement to transfer the assets, marketing rights and, eventually, marketing authorization...

TKPYY : 16.5900 (-0.90%)
TINLY : 17.6200 (-0.09%)
TAK : 16.71 (-0.24%)
Takeda Canada Celebrates Resilient Rare Stars on Rare Disease Day

Takeda Canada Celebrates Resilient Rare Stars on Rare Disease Day

TKPYY : 16.5900 (-0.90%)
Takeda Provides Updates on Phase 1/2 Clinical Trials of Novavax' and Moderna's COVID-19 Vaccine Candidates in Japan

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) announced today that the first subject was dosed in its Phase 1/2 immunogenicity and safety study of Novavax' COVID-19 vaccine candidate (TAK-019)...

TKPYY : 16.5900 (-0.90%)
TAK : 16.71 (-0.24%)
Intercept Appoints Dagmar Rosa-Bjorkeson to Its Board of Directors

Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced...

MESO : 9.60 (+0.73%)
TKPYY : 16.5900 (-0.90%)
ICPT : 21.66 (-6.01%)
Takeda Receives Prestigious EURORDIS 2021 Black Pearl Award for Patient Engagement

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) ("Takeda") Takeda has been announced the winner of the EURORDIS 2021 Award for Patient Engagement in recognition of the company's unwavering commitment...

TKPYY : 16.5900 (-0.90%)
TAK : 16.71 (-0.24%)
Australia and New Zealand Prothrombin Complex Concentrate Market Worth USD 40.4 Million at 10.9% CAGR by 2027 Owing to Rising Geriatric Population

The Australia and New Zealand prothrombin complex concentrate market size is expected to experience considerable growth by reaching USD 40.4 million by 2027 while exhibiting a CAGR of 10.9% between 2020...

TKPYY : 16.5900 (-0.90%)
Takeda's Maribavir Phase 3 Clinical Trial Met Primary Endpoint of Superiority to Conventional Antiviral Therapy in Transplant Recipients With Refractory, With or Without Resistance, Cytomegalovirus Infection/Disease

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) ("Takeda") today at the 2021 Transplantation & Cellular Therapy (TCT) Meetings Digital Experience announced new, late-breaking Phase 3 data from...

TKPYY : 16.5900 (-0.90%)
TAK : 16.71 (-0.24%)
Leukemia Therapeutics Market Size Worth USD 27.78 Billion at 8.1% CAGR; Industry Leaders Such as Pfizer and Bristol-Myers to Focus Investments on Advancing Clinical Trials: Fortune Business Insights(TM)

The global leukemia therapeutics market size is projected to reach USD 27.78 billion by 2027, exhibiting a CAGR of 8.1% during the forecast period. The increasing demand for enhanced treatments for blood...

AMGN : 224.92 (-1.14%)
BMY : 61.33 (-1.24%)
NVS : 85.91 (-0.92%)
PFE : 33.49 (-0.98%)
TKPYY : 16.5900 (-0.90%)
Gastrointestinal Therapeutics Market Revenue Growth Predicted by 2021-2030 | Takeda Pharmaceutical Company Limited, Valeant Pharmaceuticals International company

A consciously conceived and designed business intelligence report titled Global  by Manufacturers, Type, and Application, Forecast to 2030 by discloses a succinct analysis of the regional spectrum,...

ABT : 119.78 (-1.48%)
AGN : 193.02 (+0.02%)
AZN : 48.38 (-1.08%)
AVY : 175.21 (-2.07%)
BAYRY : 15.3000 (-2.65%)
EVKIY : 17.2200 (+5.45%)
GSK : 33.61 (-2.24%)
TKPYY : 16.5900 (-0.90%)
TYC : 45.59 (+1.29%)
VRX.TO : 30.80 (-3.33%)
Global $11.66 Billion Antacid (Tablet, Liquid, Others) Market Forecast to 2027

, /PRNewswire/ -- The report has been added to offering.

BAYRY : 15.3000 (-2.65%)
GSK : 33.61 (-2.24%)
PFE : 33.49 (-0.98%)
TKPYY : 16.5900 (-0.90%)

Key Turning Points

3rd Resistance Point N/A
2nd Resistance Point 17.1900
1st Resistance Point 16.8900
Last Price 16.5900
1st Support Level 16.3200
2nd Support Level 16.0500
3rd Support Level N/A

See More

52-Week High 31.2900
Fibonacci 61.8% 25.2582
Fibonacci 50% 23.3950
Fibonacci 38.2% 21.5318
Last Price 16.5900
52-Week Low 15.5000

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar